Bausch + Lomb Corporation (BLCO)
| Market Cap | 6.13B +19.0% |
| Revenue (ttm) | 5.32B +8.9% |
| Net Income | -171.00M |
| EPS | -0.48 |
| Shares Out | 357.17M |
| PE Ratio | n/a |
| Forward PE | 16.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 403,112 |
| Open | 17.16 |
| Previous Close | 17.13 |
| Day's Range | 16.94 - 17.30 |
| 52-Week Range | 13.77 - 18.92 |
| Beta | 0.55 |
| Analysts | Buy |
| Price Target | 18.63 (+8.63%) |
| Earnings Date | Jul 29, 2026 |
About BLCO
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during heali... [Read more]
Financial Performance
In 2025, Bausch + Lomb's revenue was $5.10 billion, an increase of 6.47% compared to the previous year's $4.79 billion. Losses were -$360.00 million, 13.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for BLCO stock is "Buy." The 12-month stock price target is $18.63, which is an increase of 8.63% from the latest price.
News
Bausch + Lomb Transcript: Study result
A novel dual-action dry eye therapy demonstrated rapid, significant efficacy at day 15 with reduced dosing and strong tolerability, guiding a focused phase III strategy. BL1332, a potent TRPV1 antagonist, showed dramatic pain relief in a phase I-B study, supporting broader development in ocular pain. Both assets are expected to drive substantial long-term growth.
Bausch + Lomb Slides: Study result
Bausch + Lomb has posted slides in relation to its latest quarterly earnings report, which was published on August 24, 2026.
Bausch + Lomb Press release: Study result
Bausch + Lomb issued a press release on August 24, 2026, disclosing material business information to investors.
Bausch + Lomb announces Board of Directors update
Bausch + Lomb (BLCO) announced changes to its Board of Directors. At the request of Bausch Health Companies, which has held a majority ownership position in Bausch + Lomb since…
Bausch + Lomb reaffirms FY26 revenue $5.44B-$5.54B, consensus $5.49B
Bausch + Lomb (BLCO) reaffirms the full-year 2026 guidance it raised on July 29, 2026, including revenue of $5.44B-$5.54B and Adjusted EBITDA excluding Acquired IPR&D of $1.025B-$1.075B Published firs...
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the ...
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its...
Bausch + Lomb price target raised to $21 from $20 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Bausch + Lomb (BLCO) to $21 from $20 and keeps a Buy rating on the shares. The company raised…
Bausch + Lomb price target raised to $23 from $21 at UBS
UBS raised the firm’s price target on Bausch + Lomb (BLCO) to $23 from $21 and keeps a Buy rating on the shares.
Bausch + Lomb Earnings Call Transcript: Q2 2026
Q2 2026 saw 8% revenue growth and 28% adjusted EBITDA growth, with strong performance across all segments and significant margin expansion. Guidance for full-year revenue and EBITDA was raised, supported by robust cash flow and continued deleveraging.
Bausch + Lomb Earnings release: Q2 2026
Bausch + Lomb released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Bausch + Lomb Slides: Q2 2026
Bausch + Lomb has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Bausch + Lomb Quarterly report: Q2 2026
Bausch + Lomb has published its Q2 2026 quarterly earnings report on July 29, 2026.
Bausch + Lomb Upgrades Full-Year Outlook on Strong Quarter
The eye health company raised its full-year guidance across the board, bumping its revenue target up by $20 million to a new range of $5.44 billion to $5.54 billion.
Bausch + Lomb reports Q2 adjusted EPS 15c, consensus 16c
Reports Q2 revenue $1.394B, consensus $1.37B. “Broad-based revenue growth, leverage in the P&L, margin expansion and conversion to cash flow. These have been themes since we unveiled our three-year pl...
Bausch + Lomb raises FY26 revenue view to $5.440B-$5.540B from $5.420B-$5.520B
Consensus is for FY26 revenue $5.47B. Raises FY26 Adjusted EBITDA view Excluding Acquired IPR&D to $1.025B-$1.075B from $1.010B-$1.060B.
Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-qua...
Bausch + Lomb initiated with a Buy at UBS
UBS analyst Patrick Wood initiated coverage of Bausch + Lomb (BLCO) with a Buy rating and $21 price target The eyecare sector is healthier than expected, with resilient U.S. consumer…
Bausch + Lomb initiated with a Buy at UBS
UBS initiated coverage of Bausch + Lomb (BLCO) with a Buy rating and $21 price target
Bausch + Lomb launches EyeGility Inserter in U.S.
Bausch + Lomb (BLCO) announced the U.S. launch of the EyeGility Inserter preloaded IOL delivery system. “The enVista IOL platform has long been appreciated by surgeons for its glistening-free optic…
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launc...
Bausch + Lomb says Phase 2 study of BL1107 did not achieve primary endpoint
Bausch + Lomb (BLCO) Corporation announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual…
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline result...
Bausch + Lomb introduces Orphia AI-powered digital health platform
Bausch + Lomb (BLCO) announced the creation of Orphia, a new AI-powered digital health platform built on the belief that eye care providers should spend less time managing disconnected tools…
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
VAUGHAN, Ontario, & MENLO PARK, Calif.--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today an...